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Abstract
Background: DNA methylation plays an important role in the process of tumorigenesis.
Identifying differentially methylated genes or CpG islands (CGIs) associated with genes between
two tumor subtypes is thus an important biological question. The methylation status of all CGIs in
the whole genome can be assayed with differential methylation hybridization (DMH) microarrays.
However, patient samples or cell lines are heterogeneous, so their methylation pattern may be very
different. In addition, neighboring probes at each CGI are correlated. How these factors affect the
analysis of DMH data is unknown.
Results: We propose a new method for identifying differentially methylated (DM) genes by
identifying the associated DM CGI(s). At each CGI, we implement four different mixed effect and
generalized least square models to identify DM genes between two groups. We compare four
models with a simple least square regression model to study the impact of incorporating random
effects and correlations.
Conclusions: We demonstrate that the inclusion (or exclusion) of random effects and the choice
of correlation structures can significantly affect the results of the data analysis. We also assess the
false discovery rate of different models using CGIs associated with housekeeping genes.
Background
DNA methylation is the addition of a methyl group
(CH3)t ot h e5 ’s cytocine (C) at a CG site. It can be
inherited without changing the original DNA sequences.
This epigenetic modification plays an important role in
regulating gene expression, and it may cause tumor
suppressor gene silencing [1]. Over the last two decades,
many biological and computational studies have been
done to investigate the methylation patterns in different
tissues. These studies either focus on candidate genes
such as p16 and RASSF1A [2] or on different chromo-
somes [3-7]. Most of these studies focus on cancer since
methylation patterns are changed in neoplasia. These
changes may include regional or genome-wide gain or
loss of methylation [8]. In order to gain a genome-wide
understanding of how changes in methylation affect
tumor growth, the DMH protocol [9-11] has been used
to simultaneously assay the methylation status of all
known CGIs, genomic regions rich in CG sites [12].
Previous DMH microarray studies mainly focus on
identifying genes that are differentially methylated
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lines). They identify the genes that are hypermethylated
(more methylation in cancer than normal) or hypo-
methylated (less methylation in cancer than normal).
The data analysis of these studies mainly focuses on
identifying DM genes by identifying DM probes. For
example, an arbitrary log ratio cut off of 1.5 has been
used [13], and a Gamma-Normal-Gamma model has
been applied to identify differentially methylated probes
[14]. However, a single high or low log ratio probe may
not represent true biological signals due to the large
impact of probe affinity. This is because the intensity of
each probe is related to its sequence, and different
microarray probes may have similar sequences. There-
fore, both specific and non-specific binding could occur.
With non-specific binding, two probes against the same
region (e.g., a short CGI) may have very different
intensity values. This issue has been well known and
has been addressed in the context of gene expression
microarrays [15-18]. In addition to probe affinity, other
factors such as the polymerase chain reaction (PCR)
application effect, sample preparations, and the sensi-
tivity of scanners will also affect probe intensities [17].
Furthermore, it has been shown that neighboring probes
are highly correlated over hundreds of bases [3]. As a
result, we can not assume that all probes are indepen-
dent. In addition, because cancer patients or cell lines
may have different levels of methylation signals, it is
important to consider random effects in the model too.
Unlike previous DMH studies, this paper focuses on
identifying genes that are differentially methylated
between two tumor subtypes (or two racial groups)
rather than between normal and cancerous cells. We
propose a novel method for identifying a DM gene by
pooling all probes in its associated CGI together and
incorporating the correlation structures for probes in the
same CGI. To implement this method, we apply two
mixed effect models and two generalized least square
models to incorporate the heterogeneity of different
arrays (cell lines) and study the correlation structures
between probes. We compare the results of these four
models with the ones obtained from a simple least
square regression model and find that it is important to
incorporate the random effect and choose a correlation
structure properly.
Methods
DMH microarray protocol, data preprocessing and
description
Microarray technology has brought about a revolution in
our understanding of normal and abnormal molecular
processes. With the aid of this technology, it is now
possible to identify DNA methylation patterns in specific
regions of chromosomes or even in the entire genome.
The DMH protocol [9-11] utilizes restriction enzymes to
reduce the complexity of the genome while preserving
GC-rich regions (many of which fall in and around
CGIs) for methylation profiling. A brief outline of the
DMH protocol is described below:
Step 1
Genomic DNA samples are sonicated into 400-500 bp
fragments, and linkers are ligated to these fragments.
Step 2
The methylation status of the genome of interest can be
investigated by methylation sensitive restriction
enzymes. In this particular study, the investigation is
achieved with two methylation sensitive enzymes, HpaII
and HinPI, which have the recognition sites of CCGG
and CGCG, respectively. These restriction enzymes will
c u ta l lo ft h e s eC G - c o n t a i n i n gs i t e si ft h eC sa r en o t
methylated. These enzymes will therefore remove all
linker-ligated fragments containing unmethylated CG
dinucleotides, leaving behind fragments that are 100%
methylated or those that have no HpaII and HinPI
recognition sites.
Step 3
The DNA fragments that are not restricted are then
enriched with the polymerase chain reaction (PCR) to
provide sufficient materials for fluorescent labeling and
microarray hybridization. The DMH protocol is applied
to both test samples (e.g., cancer patient material or
cancer cell lines) and control samples (common normal
reference or paired normal tissue). Both types of samples
are labeled with their respective fluorescent dyes: Cy5
dye pseudo-colored as red for test samples and Cy3 dye
pseudo-colored as green for control samples. They are
then combined in equal quantity and competitively
hybridized to a prepared microarray slide, in particular,
an Agilent 244 K human CGI array.
In total, there are about 237,220 probes that span
25,000 CGIs found in the human genome. The majority
(about 75%) of CGIs are covered by at most 10 probes.
This information is summarized in Table 1. There is one
probe within every 100 bp region per CGI, and the
Table 1: Summary of probe numbers and CGIs
# of probes 1~2 3~10 11~15 16~20 21~30 > 30
count 2753 16580 3323 1190 721 358
Proportion 0.11 0.67 0.13 0.05 0.03 0.01
List of the count and proportion of all 24925 CGIs that have 1 to 2, 3 to
10, 11 to 15, 16 to 20, 21 to 30, and more than 30 probes.
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each probe, we use the base two log ratio of red over
green intensity, log2(Cy5/Cy3), as the observed methyla-
tion signal. Large positive log ratios show that there are
more methylations in test samples (e.g., cancer patients)
than in control samples (e.g. normal individuals). This
means that there are strong hypermethylation signals in
test samples. In contrast, large negative log ratios
indicate that there are less methylations in test than in
control samples, implying that there are strong hypo-
methylation signals in test samples. Several consecutive
probes are expected to have similar positive (or negative)
log ratios because the DNA fragments that are hybridized
to the array are about 400-500 bp.
In our example data, 38 breast cancer cell line micro-
arrays are divided into two tumor subtypes, basal-like
and luminal types [19]. Each group has 19 arrays. For
each array, the background correction is done using the
“edwards method” [20]. Dye effects are corrected using
the standard within array loess normalization in the
Bioconductor package “limma” [21]. The between array
normalization is done using the quantile method
[22,23].
In order to demonstrate the heterogeneous methylation
patterns in different tumor subtypes and the variability
in cell lines, we plot the normalized data of one CGI
associated with the gene FOXD2 as shown in Figure 1. In
this figure, the probes are ordered according to their
physical location. The left three plots are for luminal cell
lines, and the right three plots are for basal-like ones.
Neighboring probes in each cell line tend to have similar
methylation signals. Cell lines belonging to the same
tumor subtypes have similar methylation patterns. For
example, the methylation signals of the three luminal
cell lines are stronger than the ones in the basal-like
subtype. Our goal is to identify those CGIs (and their
associated genes) that are differentially methylated
between two tumor subtypes.
Statistical models
In order to identify differentially methylated genes
between two tumor subtypes, we propose the idea of
identifying differentially methylated CGIs associated
with them. That is, we build models to identify
differentially methylated CGIs, then determine whether
a gene is methylated (either at its promoter region or
inside of the gene) by examining if there is any
significant methylation difference at the CGI(s) asso-
ciated with this gene. This method is different from the
others that identify differentially methylated genes by
focusing on identifying differentially methylated probes.
Instead, we put the information of all probes at each CGI
together to conduct analysis using different mixed effect
and generalized least square models.
A mixed effect model includes fixed effect(s) and
random effect(s). A fixed effect is usually a well-defined
population factor with finite levels. We are interested in
estimating different levels of a fixed effect and testing to
see if they are significantly different. For example, in our
DMH data the tumor subtype factor, which has two
levels, basal-like and luminal types, is a fixed effect and
we want to test to see if the methylation levels of these
two subtypes are significantly different from each other.
A random effect is related to some individual experiment
units that are selected from a larger (potentially infinite)
underlying population and represent a certain amount
of random variation. For example, the cell lines (or
arrays) within each subgroup can be thought of as
random samples from their representative population.
However, we are not particularly interested in the
differences between the cell lines within the same
population. As such, a random effect component is
included to model the variability. The inclusion of a
random effect can help us generalize the analysis result
to the whole population.
Furthermore, each cell line can be considered as a
“block” of probes, which will allow us to investigate the
correlation structure between probes within the same
array. Alternatively, a generalized least square model can
also be used to study correlations among probes of a CGI
within the same cell line/array. Various models may be
used to study such correlations. In this paper, we apply
two commonly used structures. One is “compound-
symmetry” correlation; that is, all within-group errors are
assumed to have equal correlations. Another one is
based on the autoregressive model in which we assume
data points are observed at integer time (or location)
points, and the current observation is a linear function of
previous ones and an error term [24].
Although we know neighboring probes are correlated, it
is still unclear what specific correlation structure is the
best fit. In addition, it is not clear how the random
variation among different cell lines (in the same tumor
subtype) will affect the analysis results. Therefore, we
explore the following four models: (1) the mixed effect
model with the array effect as a random effect, M1 (mix);
(2) the mixed effect model with the array effect as a
random effect and the probe correlation structure
modeled using an autoregressive model of order one
(AR1), M2 (mix.AR1); (3) the generalized least square
model with a compound symmetry correlation structure,
M3 (gls.comSym); and (4) the generalized least square
model with an AR1 model of correlation structure, M4
(gls.AR1).
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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(page number not for citation purposes)In the following four models, we use g to represent
the group index with g = 1 and 2 corresponding to
tumor subtypes: basal-like and luminal types. Likewise,
p is the probe index (p =1 ,. . . ,P ,w h e r ePi st h et o t a l
number of probes in one CGI). a is the array (or cell
line) index (a =1 ,2 ,. . . ,N ,w h e r eNi st h et o t a ln u m b e r
of arrays). ag and bp represent the group and probe
effects, and they are fixed effects. ga is the random effect.
εgpa is the residual error. ga and εgpa are independent in
all models.
Figure 1
The normalized data of a 16 probe-CGI across tumor subtypes. The normalized data of 16 probes at one CGI
(associated with FOXD2 gene) for 6 cell lines. The left three plots with “Lu:” in the title of each plot are for luminal cell lines.
The right three plots with “Bas:” in the title of each plot are for basal-like cell lines. The y-axis is the log ratio of methylation
signals at each probe. The x-axis is the probe index at each CGI. Probes are ordered according to their physical locations, and
the distance between two consecutive probes is roughly 50 bp.
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For the above models, we are interested in testing the
null hypothesis (H0) that there is no methylation
difference between the two tumor subtypes, i.e., a1 = a2,
at each CGI. If the test p-value of one CGI is less than
a certain threshold, then it is indicative of strong
evidence that this CGI and its associated gene(s) are
differentially methylated between two tumor subtypes. All
the above mixed effect models and generalized least
square models are implemented for each CGI using the
R package “nlme” [24].
Results
Comparisons of different models
In order to see the impact of using different correlation
structures and including or excluding random effects, we
compare the above four models with the simple least
square regression model M0 (lm), which does not
incorporate any correlation structure and only has fixed
effects, that is, ygpa = ag + bp + εgpa, εσ gpa
iid
N ~( , ) 0
2 for
any g, p and a. The test results of all five models, that is,
the numbers of CGIs with p-values < 0.05, are
summarized in Table 2. The overlaps of these models
are shown in Figure 2. In addition, we also plot the
p-values of all CGIs from four models (M1, M2, M3 and
M4) against the p-values of the model M0, which
does not incorporate correlations between probes (see
Figure 3). The two top plots of this figure are the models
with random effects included (models M1 and M2). The
model M1 has larger p-values than M0 at all CGIs, while
Table 2: The number of CGIs with p-values < 0.05 in five models
Models M1 M2 M3 M4 M0
# of CGI with p < 0.05 463 503 839 862 1048
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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(page number not for citation purposes)Figure 2
Overlaps of CGIs obtained from different models. Each plot is a set of Venn Diagrams that shows the overlap of CGIs
selected by different models. (A) is for models M0, M1 and M3.( B )i sf o rm o d e l sM 0 ,M 2a n dM 4 .( C )i sf o rm o d e l sM 1a n dM 2 .
(D) is for models M3 and M4.
Figure 3
The plots of p-values of all CGIs. The plots of p-values of all CGIs obtained from models M1, M2, M3 and M4 against
the p-values from the linear model M0: (A) M1 versus M0, (B) M2 versus M0, (C) M3 versus M0, and (D) M4 versus M0.
The white dashed line is the straight line with an intercept of 0 and a slope of 1.
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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The two bottom plots of Figure 3 are the models without
any random effect included. These plots show that,
compared with the linear model (M0), models M3 and
M4 have some CGIs with larger p-values and some with
smaller ones than M0.
The mixed effect models (M1 andM2) identify roughly half
as many DM CGIs as identified by the non-random effect
models(M3,M4andM0).Thiscouldbe due tothe fact that
these mixed effect models include the random effect to
incorporate the variation of different cell line samples.
When the random effect is included, a positive correlation
structure is introduced to the model. Therefore, we tend to
get larger p-values. This is useful in reducing bias due to the
noise, which could be caused by many unmeasured factors,
and may introduceimproper negative correlationsthat may
not be consistent with the underlying methylation pattern
and the DMH microarray protocol.
Because the mixed effect models appear to be better
suited for the purpose of analyzing CGI methylation
data, we focus on further comparing M1 with M2. We
find that 45 CGIs are obtained from the model M1 but
not from M2, the majority (30/45 = 67%) of which have
correlations equal to zero in the M1 model and most of
which (except 2/45 CGIs) have positive correlation
estimates in M2; for those 85 CGIs that are selected by
the model M2 but not by M1, the majority (72/85 =
85%) have correlations equal to zero in the M1 model,
a n dm o s to ft h o s e8 5C G I s( e x c e p t8 / 8 5o ft h e m )h a v e
negative correlations in model M2 (see the top two plots
in Figure 4).
Relationship between correlation estimates and the
number of probes
In the previous section we explore and compare the
results and features of those four different models (M1,
M2, M3 and M4) using the linear model M0 as the base
line. The comparison results show that the p-values are
related to the correlation structures (estimates). As far as
the correlation between probes is concerned, our under-
standing about the microarray protocol is that this might
be related to the number of probes at each CGI.
According to the DMH protocol, several consecutive
Figure 4
Correlation estimate comparison plot. Plots of correlation estimates for CGIs that are selected by one model but not
by another one: (A) 45 CGIs by M1 but not by M2, (B) 85 CGIs by M2 but not by M1, (C) 256 CGIs by M3 but not by M4,
and (D) 279 CGIs by M4 but not by M3.
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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(page number not for citation purposes)probes (across several hundred bases) in the same CGI
are meant to have similar log ratios; that is, they are all
positive (or negative) and have similar values. However,
for much longer CGIs with many probes, the methyla-
tion pattern can vary along the CGI; that is, there could
be very strong methylation signals in one end of the CGI,
but not many signals in the other end. For the shorter
CGIs with only 3 or 4 probes, the methylation signals of
these probes are supposed to be similar. However, our
exploration of the data shows that this may not be true
due to the noise of the data. In order to fully understand
the relationship between the correlation estimate and
number of probes at each CGI, we make plots for all
CGIs as shown in Figure 5.
In Figure 5, “A” is the correlation estimates of the model
M1, that is, the estimates of the intra-class correlation,
ρσσσ 11
2
1
22 =+ /( ), for all CGIs. These estimates are
only related to the variances of the random effect and the
residual error, so they are all positive. “B” is the
correlation estimates (r2) of the model M2 for all
CGIs, some of which have positive correlations, while
the others have negative ones. “C” is the correlation
estimates of the model M3 for all CGIs, the majority of
which are positive. “D” is the correlation estimates of the
model M4 for all CGIs. About half of these estimates are
p o s i t i v ea n dh a l fa r en e g a t i v e .
Figure 5 shows that the CGIs with a small number of
probes tend to have very large positive or negative
correlations. Large positive correlation estimates could
be more consistent with the underlying methylation
pattern and the DMH design, while large negative
correlations could be due to some artificial effects. In
order to understand the correlation pattern better, we
compare the correlation estimates of models M1 and M3
since these two models have similar correlation struc-
tures. The correlation estimates of these two models are
Figure 5
Plots of correlation estimates and number of probes. Plots of the correlation estimates obtained from different models
(M1 - M4) against the number of probes: (A) model M1, (B) model M2, (C) model M3, and (D) model M4. In each plot, the
horizontal axis is the number of probes and the vertical axis is the correlation estimates obtained from each model.
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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12080 CGIs have positive correlations in both models
M1 and M3. 9210 CGIs have negative correlations in M3,
but their correlations are equal to 0 in the model M1.
In order to explore whether the negative or positive
correlation estimates have a major impact on the final
conclusion of the significant differentially methylated
CGIs, we study the CGIs with p < 0.05 in models M1 and
M3, that is, those 463 CGIs with p < 0.05 in model M1
(mix) and those 839 CGIs with p < 0.05 in model M3
(gls.comSym). In fact, those 463 CGIs from M1 are part
of those 839 CGIs. For the remainder of those 376 CGIs,
85% (319/376) of them have negative correlation; that
is, the 376 small p-values from model M3 are mainly
due to the negative correlations. Besides the comparisons
of models M1 and M3, we also compare models M2 and
M4. There are 503 CGIs with p < 0.05 in M2 (mix.AR1),
and 862 CGIs with p < 0.05 in M4 (gls.AR1). Among
these CGIs, 503 CGIs from model M2 are in fact part of
those 862 CGIs from M4. They have p < 0.05 in both
models M2 and M4. 359 CGIs have p < 0.05 only in the
M4 (gls.AR1) model, but not in M2 (mix.AR1). Figure 7
shows that, for those 359 CGIs, the correlation estimates
from M4 are similar to the ones from M2. However,
these 359 CGIs have much larger p-values in the model
M2 than in M4. This may be due to the fact that
microarray samples are heterogeneous and the model
M4 does not include random effects.
Assessing false discovery rate
As shown in the previous section, the inclusion (or
exclusion) of random effects and the choice of correla-
tion structure can greatly affect the results. Therefore, it is
very important to access the false discovery rate (or
specificity) of all models. In order to do so, we borrow
some information from housekeeping (HK) genes and
treat them as known “non-differentially methylated
genes”. This is because HK genes are known to maintain
the basic function of a cell and are relatively stable, so
their methylation signals are not supposed to be very
different between two groups. Figure 8 shows the
methylation pattern of a HK gene, where the log ratios
of most probes in all six cell lines (three in each tumor
subtype) are close to zero. In this paper, we use 205 HK
genes selected from 575 such genes [25]. These 205
genes are associated with only one CGI and there is at
least one promoter probe. The results of comparing the
five models using 205 HK genes are listed in Table 3.
This table shows that the mixed effect models (i.e., M1
and M2) identify fewer HK genes. In particular, the
Figure 6
Correlation estimates of M1 and M3.T h i sp l o t
compares the correlation estimates obtained from models
M1 and M3. 12080 CGIs, corresponding to the points above
the horizontal line, have positive correlations in both M1 and
M3. 9210 CGIs, corresponding to the points blow the
horizontal line, have negative correlations in only M3.
Figure 7
Correlation estimates of CGIs obtained from model
M4 but not M2. This plot compares the correlation
estimates of 359 CGIs that are obtained from model M4 but
not M2. That is, their M4 model p-value is less than 0.05, but
their M2 model p-value is larger than 0.05.
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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T h en o r m a l i z e dd a t ao ft h eh o u s e k e e p i n gg e n eR A D 9 A . The normalized data of 11 probes at one CGI (associated with
RAD9A gene) for 6 cell lines. The left three plots with "Lu:" in the title of each plot are for luminal cell lines. The right three
plots with "Bas:" in the title of each plot are for basal-like cell lines. The y-axis is the log ratio of methylation signals
at each probe. The x-axis is the probe index at each CGI. Probes are ordered according to their physical locations,
and the distance between two consecutive probes is roughly 50 bp.
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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half as many as that identified by models M4 and M0,
leading to a smaller false discovery rate. This result is
consistent with the one shown in Table 2; that is, the
number of CGIs identified by non-random effect models
(especially the model M0) is about twice as large as the
one identified by the model M1. These results suggest
that mixed effect models may be more appropriate for
modelling the variability among cell lines within the
same group compared to the other models.
Discussion and Conclusions
We propose a new method for identifying differentially
methylated genes by identifying differentially methy-
lated CGIs. With this method, we can consider the
information of all probes in each CGI as a whole. One
advantage of this method is that we can add a “probe”
factor to account for the noise and variation due to many
unmeasured factors (e.g., effects due to PCR and human
error). Another advantage is that we can model the
correlation between probes in the same array at each
CGI. Our comparison results do show that this is
necessary as the correlations between probes can affect
the test results significantly.
Because cancer cell lines or patient samples are in general
heterogeneous, they may have very different levels of
methylation. Hence, the inclusion (or exclusion) of
random effects is crucial in the data analysis. Our
assessment of the false discovery rate using HK genes
also shows that the mixed effect models (M1 and M2)
have relatively smaller false discover rates. Therefore, we
recommend using a mixed effect model instead of a
generalized least square model. As for whether to use M1
or M2, we recommend using the model M1 for the
following two reasons. First, according to the DMH
protocol, the consecutive probes are supposed to be
positively correlated. Second, the AR1 model could be
too specific for this type of noisy and complex data; that
is, ‘forcing’ a specific model like AR1 to identify the local
correlation may not be proper. As for the selected
candidate CGIs (genes), we recommend ignoring short
CGIs that have only three or four probes and have zero
correlation estimates or investigating them more care-
fully. We suggest this since methylation signals should
be very similar within 300-400 bases (covering about
three or four probes) and such a zero correlation
estimate is more than likely due to noise.
As for the sensitivity, it is very important to access this
with genes that are known to be differentially methy-
lated between two tumor subtypes. Currently, we do not
have such a list of genes. Instead, we make use of some
known biological information about methylation pat-
terns [3] and the DMH protocol [9-11] to make the
above suggestions. One key assumption of linear models
is normality. In order to validate the assumption, we
used the Kolmogrov-Smironov (KS) test on the residuals
of the M1 (mix) model. After the “BH” multiple test
c o r r e c t i o n[ 2 6 ] ,n oC G I sf a i lt h eK St e s t .T h e r e f o r e ,i ti s
reasonable to assume the normal distribution.
After the within-array and between-array normalization,
outlying probes are selected and deleted if there is at
least one observation falling out of this range [Q1 - k*
(Q3-Q1), Q3 + k*(Q3-Q1)], where k = 5, Q1 and Q3 are
the 25% and 75% quantiles of the log ratios of all probes
in one CGI. Note that we choose k = 5, which is larger
than the usual inter quartile range (k = 1.5). With k = 5,
we mean to delete those probes that have outlying
observations due to noise but retain those with certain
variations for further modeling.
The main focus of this paper is to address the importance
of incorporating random effects and correlations in our
statistical models and to see how this affects the analysis
results. Therefore, the numbers of DM CGIs presented in
Table 2 are the summary based on the raw p-values, and
we have not done any multiple test correction. If we were
to conduct multiple test corrections, especially using a
stringent method, we expected that not many CGIs
would be selected any more. This could be due to two
reasons. First, the underlying biological truth is that the
effect size is too small to survive any multiple test
corrections. Second, the sample size may not be large
enough to separate two tumor subtypes. For example, it
has been shown that among 194 cancer patients, only
a b o u t1 / 6~ 1 / 5o ft h e mh a v es t r o n g e rm e t h y l a t i o n
signals than normal individuals at the CST6 gene
transcription start site (see Figure 7 (A) of [27]).
Generally speaking, two types of cancerous cells are
much more similar than cancerous and normal cells, so
many more samples might be needed to really separate
the methylation patterns of two tumor subtypes.
In this paper, we implement four models (M1, M2, M3
and M4) in all 22,000 CGIs, which have at least three
probes. For each CGI, a p-value is obtained at each
model to indicate whether there is a significant
methylation difference between two tumor subtypes.
The p-values for long CGIs (e.g., the ones with more than
20 probes) may not have the same meaning as the ones
for the shorter CGIs (e.g., with less than 10 probes). We
also discover that the long CGIs easily fail the KS
Table 3: The number of housekeeping genes with p < 0.05 in five
models
Models M1 M2 M3 M4 M0
P < 0 . 0 5 6891 2 1 1
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
Page 11 of 14
(page number not for citation purposes)normality test (i.e., raw p-value < 0.05) and have
relatively smaller R
2. Therefore, we recommend utilizing
the following two methods to deal with long CGIs. First,
break the long CGIs into a few parts with each part
consisting of several probes (e.g., around 10 probes).
Second, fit the linear model to probes at each CGI using
only the probes that are located in the promoter or first
exon region of certain genes, and if necessary, divide
them into small parts. There are only a small percentage
of CGIs (about 4%) with more than 20 probes, so this
will not affect our conclusion about the relationship
between correlation estimates and the number of probes.
There are other HK gene lists provided by some recent
papers [28,29]. After comparing the lists from these
papers with the one we used [25], we found our HK gene
list is still a better choice for our purpose because it has
the following two advantages. First, it is obtained using
relatively a larger number of tissues than the ones used
in [28,29]. Second, the microarray data set used in [25]
has replicates which helps reduce some measurement
noise, making results more trustworthy.
The overlap of those significantly differentially methy-
lated CGIs obtained from all five models is in fact the
overlap of the CGIs from models M1 and M2, which are
418 CGIs. These CGIs are associated with 355 genes with
known annotations. Ten genes sets (pathways) are
enriched using the Molecular Signature Database
(MSigDB) to conduct the gene set overlapping analysis
http://www.broad.mit.edu/gsea/ (see Table 4 for the
pathways and the genes that overlaps with these path-
ways). Several of these pathways are also identified by
other breast cancer gene expression analysis methods
that incorporate the pathway information [30,31]. This
indicates that the methylation signatures of the genes in
these ten pathways could play a very important role in
breast cancer studies. In addition, six genes (PIK3R2,
KDR2, EPOR, MPL, BMP2, and PPP1CB) are enriched in
at least two pathways. Five of these six genes are closely
related to various cancers. In particular, PIK3R2, which is
enriched in four pathways, belongs to the PIK3 gene
family that plays an important regulatory role in various
cancer related signalling pathways [32]. It has recently
been identified as a significant negative prognosis factor
for ovarian cancer [33]. KDR, also known as VEGFR2
gene, is important in tumor angiogenesis [34]. Due to its
crucial role in angiogenesis, KDR could be used as the
molecular target of early diagnosis and treatment in
cancer [35,36]. EPOR is the receptor of the recombinant
human erythropoietin (Epo) that is used to treat tumor
related anemia [37]. The MPL mutation occurs in acute
megakaryoblastic leukemia [38]. Aberrant BMP2 promoter
CGI methylation has been found in both colon cancer and
gastric cell lines, and the resultant loss of BMP2 expression
may be related to gastric carcinogenesis [39].
CGIs could cover different parts of genes, and CGIs from
promoter regions may differ from those found in the
gene body with respect to their methylation levels and
neighboring probe correlation levels. However, this does
not affect the performance of our models since they are
completely general and analyze each CGI separately.
Therefore, they can accommodate the methylation level
differences and probe correlation strength for each CGI.
After the analysis is done, we can do further bioinfor-
matic studies for the CGIs we identified. For example, we
can investigate the relationship between CGI locations
and probe correlation estimates. Studying the genes
identified by the model M1, we found that 45% of
Table 4: Gene set enrichment analysis
Gene sets p-value Genes in pathways
Neuroactive ligand receptor interaction 2.13 e-5 EDNRB, GABBR1, GRIK2
Cytokine cytokine receptor interaction 3.1 e-4 KDR, EPOR, MPL, TGFB2, BMP2
Regulation of actin cytoskeleton 9.21 e-4 PIK3R2, PPP1CB, LIMK2, ARPC1B
Focal adhesion 4.81 e-3 KDR, PIK3R2, PPP1CB, COL2A1, COL5A1
Natural killer cell mediated cytotoxicity 4.97 e-3 PIK3R2, NFATC3
Jak-STAT signaling pathway 5.63 e-3 EPOR, MPL, PIK3R2
Oxidative phosphorylation 6.17 e-3 ATP5A1, ATP12A
Smooth muscle contraction 6.53 e-3 PLCB3, CALM1, PRKCE
Purine metabolism 8.35 e-3 POLA1, ADA, IMPGH2
MAPK signaling pathway 1.14 e-2 MAP3K7, CACNA1C, CACNA1H, MKNK1, NTRK1, MAPKIP2,
CACNG8, RASGRF2, TGFB2
BMC Bioinformatics 2009, 10:404 http://www.biomedcentral.com/1471-2105/10/404
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(page number not for citation purposes)promoter CGIs have a positive correlation estimate, and
55% of non-promoter CGIs have a positive correlation.
This may indicate that the probe correlation estimates
are location dependent.
Although we have only presented the implementation and
comparisons of the models in one data set in this paper to
focusourdiscussion,infact,wehavedonethesameanalysis
and comparison on an endometrial cancer data set of two
racial groups (African Americans and Caucasians) and got
the same conclusions. In addition, although the results of
this paper are mainly for the DMH microarray data, the
methods could be applied to data generated by the other
methylation microarray protocols such as Methylated DNA
Immunoprecipitation (MeDIP) assay.
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